rituximab biosimilar / GE Healthcare, iBio, CC-Pharming - LARVOL DELTA

RESIDUAL DISEASE DETECTED BY PET/MRI IN CNS RELAPSE OF PRIMARY MEDIASTINAL B CELL LYMPHOMA (ASPHO 2020) - "Objectives: To describe the use of PET/MRI to identify residual disease in isolated CNS lymphoma Design/ A 15-year-old with PMBCL was treated with dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin, rituximab, and achieved complete metabolic remission at the end of treatment based on PET/CT...He received CNS directed chemotherapy (high-dose methotrexate, cytarabine, brentuximab, cytarabine, and etoposide) but had disease progression...He went on to receive craniospinal irradiation with pembrolizumab and PET/MRI showed a residual basal ganglia mass but resolution of leptomeningeal disease and abnormal PET activity. PET/MRI identified a small CNS lesion that was decreasing in size but with increased PET activity that ultimately progressed. PET/MRI technology offers functional imaging with the benefit of higher resolution images that can improve disease monitoring in CNS lymphoma ."

Residual disease • CNS Disorders • Diffuse Large B Cell Lymphoma • Hematological Disorders • Hematological Malignancies • Lymphoma • Mediastinal B Cell Lymphoma • Non-Hodgkin’s Lymphoma • Oncology • Pediatrics • Transplantation • FDG PET • MRI

iBio reports progress on its bio-better rituximab collaboration with CC-Pharming (GlobeNewswire) - "iBio...presented results of the application of its new FastGlycaneering Development Service™ to enhance potency of recombinant proteins at last week’s Antibody Engineering & Therapeutics conference in San Diego, CA. Specifically, the presented data demonstrated the ability to deploy iBio’s glycan engineering technologies and plant-based manufacturing platform to rapidly develop and produce biobetters, such as the biobetter rituximab ('iBio Rituximab') product candidate currently being developed in collaboration with CC-Pharming Ltd."

Clinical

iBio and South Africa’s AzarGen advance development of biosimilar Rituxan - "Pursuant to the SOW1, iBio will manufacture research quantities of a plant-made rituximab for AzarGen using iBio’s proprietary FastPharming system. Following batch production, the drug product candidate will undergo testing via iBio CDMO’s bioanalytical services."

Licensing / partnership

iBio and CC-Pharming to launch plant-based rituximab in China (Biopharma Reporter) - "iBio grants CC-Pharming exclusive license to commercialize rituximab in China, as well as a research license to bring its FastPharming technology to the country."

Licensing / partnership

iBio and CC-Pharming Expand Business Collaboration in China (GlobeNewswire, iBio, Inc.) - "NEW YORK, Aug 26, 2019 (GLOBE NEWSWIRE) -- iBio, Inc (NYSE AMERICAN:IBIO) today announced that it has expanded the scope of its business venture with CC-Pharming Ltd by granting it an exclusive, royalty-bearing commercial license to iBio’s bio-better rituximab (“iBio Rituximab”) product candidates for the territory of China. Rituximab was first approved by the U.S. Food and Drug Administration in 1997 for treatment of certain B cell non-Hodgkin lymphomas."

Clinical • Commercial • Regulatory

iBio Inc. Company Presentation (BIO 2019) - "iBio will present a real case study on the process and collaboration necessary to produce a bio-better rituximab for countries where access to these drugs is limited. The presentation will show the uses of plant transient expression and Plant-made Pharmaceuticals as a recognized method of developing therapeutics, and how this accelerates the ability of developing countries, where budgets can be extremely tight, to quickly be up and running for targeted therapies. By bringing its technology to places where certain therapies or vaccines are unaffordable or nonexistent, iBio is part of life-saving projects."